# Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption

- Source: PR Newswire M&A
- Published: 2026-11-05T13:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/lakewood-amedex-biotherapeutics-announces-completion-of-series-c-convertible-preferred-stock-redemption-302930368.html
- Canonical: https://groundlevelnews.com/story/lakewood-amedex-biotherapeutics-announces-completion-of-series-c-conve-d5cafe/

SARASOTA, Fla., Nov. 5, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) (the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._